论文部分内容阅读
肝性脑病是由急、慢性肝病者肝功能衰竭所致的一种临床综合征。近年来,动物实验及临床实践均证明,增高的γ-氨酪酸(GA-BA)介导的抑制性神经传导可促进肝性脑病的发生。为研究GABA/苯二氮(?)类受体拮抗剂氟马西尼(Flumazenil)治疗肝性脑病的可能性,作者对14例肝硬化门脉高压所致的肝性脑病患者(男、女各7例)静脉注射氟马西尼。首次静注本品0.2mg,如3分钟后病人神志无明显改善,再静注0.2mg及估价症状改善状况,或每隔3分钟注射1次,总剂量在0.4～9.6mg之间。用药前后分别作脑病
Hepatic encephalopathy is a clinical syndrome caused by liver failure in acute and chronic liver disease. In recent years, animal experiments and clinical practice have proved that elevated inhibitory nerve conduction of gamma-aminobutyric acid (GA-BA) can promote the occurrence of hepatic encephalopathy. In order to study the possibility of GABA / benzodiazepine receptor antagonist Flumazenil in the treatment of hepatic encephalopathy, the authors evaluated 14 patients with hepatic encephalopathy (men and women Each 7 cases) intravenous flumazenil. The first intravenous injection of this product 0.2mg, such as 3 minutes after the patient’s consciousness no significant improvement, then intravenous injection of 0.2mg and evaluation of symptoms to improve the condition, or injected every 3 minutes, the total dose of between 0.4 ~ 9.6mg. Before and after treatment for brain disease